If you're building a long-term portfolio, high-quality ASX shares are essential.
The best ASX opportunities often come from companies with scale, strong management, and exposure to powerful growth trends. Get that mix right, and you give yourself a real chance of compounding returns over time.
Here are two ASX shares that could be worth buying and holding for the long term.
Image source: Getty Images
ResMed Inc (ASX: RMD)
ResMed offers a compelling growth story. The $48 billion ASX share is a global leader in sleep apnea and respiratory care devices.
Its products help millions of patients worldwide, and demand is growing. Why? Two key drivers: ageing populations and rising awareness of sleep health.
Sleep apnea is still underdiagnosed globally. As detection improves, more patients enter the treatment funnel. That creates a long runway for growth.
ResMed also has a strong digital ecosystem. Its cloud-connected devices and software platforms provide ongoing patient monitoring and data insights. That builds recurring revenue and strengthens customer relationships.
Global scale, market leadership, and exposure to a growing healthcare need are the key strengths of this ASX share.
Risks are not to be overlooked though. Competition and pricing pressure are ongoing challenges. There's also regulatory risk across different markets.
But ResMed has proven it can adapt and keep growing. The ASX healthcare share has also lost 21% in value over 6 months, which makes it more appealing to jump in.
Hub24 Ltd (ASX: HUB)
Hub24 is a growth machine — and it's showing no signs of slowing.
Its 1H FY26 result was impressive. Net inflows hit a record $10.7 billion. Revenue jumped 26% to $245.9 million. Even better, underlying net profit surged around 60% as the business scaled.
Funds under administration climbed to $152.3 billion. And the board rewarded shareholders with a 50% increase in the interim dividend.
That's exactly the kind of operating leverage investors want to see.
But the real story is structural.
Hub24 is benefiting from a shift in the wealth industry. Financial advisers are increasingly consolidating onto fewer platforms — a trend often called "platform monogamy." The $7 billion ASX share is winning that battle. It now has more than 5,200 advisers using its platform, and that number keeps growing.
Hub24's biggest strengths are strong inflows, rising market share, and a scalable business model.
Risks are never far away, with valuation being the big one. The ASX share has surged and trades on premium multiples. That leaves little room for error.
Competition is also heating up as legacy players upgrade their technology.
The bottom line
Hub24 and ResMed operate in very different industries. But they share key traits: strong growth drivers, scalable models, and leadership positions.
One is riding the wealth platform shift. The other ASX share is tapping into global healthcare demand.
Neither is cheap. But for long-term investors, quality rarely is.
If they continue executing, both could deliver strong returns over the long term.
